Cleo SG Advances Global Technology Licensing for Vaccine Pipeline... "Participates in International Vaccine Industry Conference"

CreoSG announced on the 25th that it will participate in the ‘2024 Bio Industry Expo International Vaccine Industry Conference’ hosted by the Vaccine Commercialization Technology Support Center. Through this international conference, CreoSG plans to achieve results in its global pipeline.

The International Vaccine Industry Conference will be held on the 26th in Andong City, a global vaccine hub, under the theme of ‘Establishing a Global Cooperation System and Vision for Responding to New and Mutant Infectious Diseases.’

CreoSG intends to discuss its proprietary new drug pipeline business with overseas vaccine experts and government officials at the conference. Centered on its universal vaccine development platform ‘SUV-MAP,’ the company has secured various vaccine candidates including those for MERS, Zika, Severe Fever with Thrombocytopenia Syndrome (SFTS), and Hemorrhagic Fever with Renal Syndrome (HFRS).

Based on SUV-MAP, CreoSG has confirmed the efficacy of its Zika vaccine and recently succeeded in developing the world’s first vaccine candidate capable of simultaneously preventing SFTS and HFRS through a national project. Since diseases like Zika and SFTS have high incidence rates in Southeast Asia and the government is actively promoting vaccine development, the company expects outcomes such as license-outs starting from this conference.

A CreoSG representative stated, “We decided to participate in this conference, hosted by Korea’s top vaccine institutions, to actively promote global technology transfer of our vaccine pipeline. Through the conference, we plan to share development achievements of our pipeline and introduce our proprietary vaccine development technology to establish partnerships with global companies.”

He added, “In the case of epidemic vaccines, development and commercialization tend to be led by the government. At this event, we will actively pursue global achievements such as license-outs and joint research and development by holding vaccine-related business meetings not only with global companies but also with overseas government officials.”

This content was produced with the assistance of AI translation services.